FR2657259A1 - Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation. - Google Patents
Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation. Download PDFInfo
- Publication number
- FR2657259A1 FR2657259A1 FR9000834A FR9000834A FR2657259A1 FR 2657259 A1 FR2657259 A1 FR 2657259A1 FR 9000834 A FR9000834 A FR 9000834A FR 9000834 A FR9000834 A FR 9000834A FR 2657259 A1 FR2657259 A1 FR 2657259A1
- Authority
- FR
- France
- Prior art keywords
- myristoyl
- phenylalanine
- myristoylation
- treatment
- medicaments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GFNNQTYRJPFJGX-NRFANRHFSA-N (2s)-3-phenyl-2-(tetradecanoylamino)propanoic acid Chemical compound CCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 GFNNQTYRJPFJGX-NRFANRHFSA-N 0.000 title claims abstract description 12
- 201000010099 disease Diseases 0.000 title claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 4
- 230000007498 myristoylation Effects 0.000 title description 6
- 239000003814 drug Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 8
- 201000011510 cancer Diseases 0.000 claims abstract description 7
- 208000030507 AIDS Diseases 0.000 claims abstract description 3
- 108010016306 Glycylpeptide N-tetradecanoyltransferase Proteins 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 241001430294 unidentified retrovirus Species 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 8
- DYUGTPXLDJQBRB-UHFFFAOYSA-N N-myristoylglycine Chemical class CCCCCCCCCCCCCC(=O)NCC(O)=O DYUGTPXLDJQBRB-UHFFFAOYSA-N 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 241001529936 Murinae Species 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 3
- 235000021360 Myristic acid Nutrition 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 241000212384 Bifora Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 102000005870 Coenzyme A Ligases Human genes 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 1
- 108010038807 Oligopeptides Chemical class 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- -1 glosettes Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DUAFKXOFBZQTQE-QSGBVPJFSA-N myristoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 DUAFKXOFBZQTQE-QSGBVPJFSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9000834A FR2657259A1 (fr) | 1990-01-25 | 1990-01-25 | Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation. |
| CA002034861A CA2034861A1 (fr) | 1990-01-25 | 1991-01-24 | Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation |
| IE24291A IE65573B1 (en) | 1990-01-25 | 1991-01-24 | Use of N-myristoyl-(S)-phenylalanine for obtaining medicinal products intended for the treatment of diseases involving myristoylation |
| JP3007188A JPH0717503B2 (ja) | 1990-01-25 | 1991-01-24 | ミリストイル化を伴う疾患の治療を意図する薬効のある生成物を得るためのｎ−ミリストイル−（ｓ）−フェニルアラニンの使用 |
| PT96571A PT96571A (pt) | 1990-01-25 | 1991-01-24 | Processo para a preparacao de composicoes farmaceuticas contendo n-miristoil-(s)-fenilalanina |
| US07/645,124 US5164414A (en) | 1990-01-25 | 1991-01-24 | Use of n-myristoyl-(s)-phenylalanine for the treatment of diseases involving myristoylation |
| AT91400163T ATE94387T1 (de) | 1990-01-25 | 1991-01-25 | Verwendung von n-myristoyl-(s)-phenylalanin zur herstellung eines medikaments zur behandlung von krankheiten mittels hemmung der myristoylierung. |
| ES91400163T ES2060310T3 (es) | 1990-01-25 | 1991-01-25 | Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion. |
| OA59940A OA09478A (fr) | 1990-01-25 | 1991-01-25 | "Utilisation de la N-myristoyl-(S)-phénylalaine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation". |
| DK91400163.1T DK0443891T3 (da) | 1990-01-25 | 1991-01-25 | Anvendelse af N-myristotyl-(S)-phenylalanin eller et additionssalt deraf med en farmaceutisk acceptabel base til opnåelse af et farmaceutisk middel og farmaceutisk middel til behandling af sygdomme ved indgribning i myristoyleringen |
| AU69987/91A AU633395B2 (en) | 1990-01-25 | 1991-01-25 | Use of n-myristoyl-(s)-phenylalanine for obtaining medicinal products intended for the treatment of diseases involving myristoylation |
| DE91400163T DE69100364T2 (de) | 1990-01-25 | 1991-01-25 | Verwendung von N-Myristoyl-(S)-Phenylalanin zur Herstellung eines Medikaments zur Behandlung von Krankheiten mittels Hemmung der Myristoylierung. |
| EP91400163A EP0443891B1 (fr) | 1990-01-25 | 1991-01-25 | Utilisation de la N-myristoyl-(S)-phénylalanine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation |
| ZA91574A ZA91574B (en) | 1990-01-25 | 1991-01-25 | Use of n-myristoyl-(s)-phenylalanine for obtaining medicinal products for the treatment of diseases involving myristoylation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9000834A FR2657259A1 (fr) | 1990-01-25 | 1990-01-25 | Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2657259A1 true FR2657259A1 (fr) | 1991-07-26 |
| FR2657259B1 FR2657259B1 (cg-RX-API-DMAC7.html) | 1994-08-19 |
Family
ID=9393082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9000834A Granted FR2657259A1 (fr) | 1990-01-25 | 1990-01-25 | Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5164414A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0443891B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPH0717503B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE94387T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU633395B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2034861A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69100364T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0443891T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2060310T3 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2657259A1 (cg-RX-API-DMAC7.html) |
| IE (1) | IE65573B1 (cg-RX-API-DMAC7.html) |
| OA (1) | OA09478A (cg-RX-API-DMAC7.html) |
| PT (1) | PT96571A (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA91574B (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5599947A (en) * | 1993-01-14 | 1997-02-04 | G. D. Searle & Co. | Fatty acid analogs and prodrugs |
| US5859052A (en) * | 1993-01-14 | 1999-01-12 | G. D. Searle & Co. | Fatty acid analogs and prodrugs |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2672598A1 (fr) * | 1991-02-11 | 1992-08-14 | Adir | Nouveaux inhibiteurs de n-myristoyltransferase, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US6407125B1 (en) | 1995-12-29 | 2002-06-18 | Novactyl, Inc. | Pharmacological agent and method of treatment |
| US6127393A (en) | 1995-12-29 | 2000-10-03 | Novactyl, Inc. | Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method |
| US6579891B1 (en) | 1995-12-29 | 2003-06-17 | Novactyl, Inc. | Agent and method for prevention and treatment of cancer in animals |
| US6743771B2 (en) | 1995-12-29 | 2004-06-01 | Novactyl, Inc. | Methods and compositions for controlling protein assembly or aggregation |
| US6441009B1 (en) | 1998-08-01 | 2002-08-27 | Novactyl, Inc. | Agent and method of preventing and treating heavy metal exposure and toxicity |
| WO2001037827A1 (en) * | 1999-10-13 | 2001-05-31 | Chacon Marco A | Therapeutic intervention to mimic the effect of caloric restriction |
| US6403618B1 (en) | 2000-02-15 | 2002-06-11 | Novactyl, Inc. | Agent and method for controlling angiogenesis |
| WO2003007876A2 (en) * | 2001-06-25 | 2003-01-30 | University Of Massachusetts | N-fatty acid-amino acid conjugates and therapeutic uses |
| DE10353806A1 (de) * | 2003-11-14 | 2005-07-07 | Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Gesundheit, dieses vertreten durch das Robert-Koch-Institut, vertreten durch seinen Präsidenten | Verwendung von Aminosäure- und Zucker-Amphiphilen zur Inaktivierung von lipidumhüllten Viren |
| US7544714B2 (en) * | 2004-07-16 | 2009-06-09 | University Of Massachusetts | Lipid-amino acid conjugates and methods of use |
| IL172896A0 (en) * | 2005-12-29 | 2006-06-11 | Yeda Res & Dev | Cxcr4 inhibition |
| CN103826623A (zh) | 2011-07-22 | 2014-05-28 | 厄尔莱克斯制药公司 | 合成致死与癌症的治疗 |
| CN104254253B (zh) | 2012-03-30 | 2017-12-29 | 奇华顿股份有限公司 | 作为食品加香化合物的n‑酰化甲硫氨酸衍生物 |
| EP2830437B1 (en) | 2012-03-30 | 2018-12-26 | Givaudan SA | N-acylated 1-aminocycloalkyl carboxylic acids as food flavouring compounds |
| BR112014023941B1 (pt) | 2012-03-30 | 2020-07-14 | Givaudan S.A. | Composição flavorizante em pó, bem como composições comestíveis de petisco e refresco em pó compreendendo a mesma |
| WO2013148991A1 (en) | 2012-03-30 | 2013-10-03 | Givaudan S.A. | N-acyl derivatives of gamma amino - butyric acid and and beta alanine as food flavouring compounds |
| EP2833739B1 (en) | 2012-03-30 | 2020-12-02 | Givaudan SA | N-acyl proline derivatives as food flavouring compounds |
| KR102045589B1 (ko) | 2012-03-30 | 2019-11-15 | 지보당 에스아 | 식품 향미 화합물로서의 n-아실-아미노산 유도체 |
| CA2868085C (en) | 2012-03-30 | 2020-09-15 | Harry Renes | Improvements in or relating to organic compounds |
| JP6463685B2 (ja) * | 2012-10-30 | 2019-02-06 | パシレックス・ファーマシューティカルズ・インコーポレイテッド | 合成致死性および癌の治療 |
| GB201317424D0 (en) | 2013-10-02 | 2013-11-13 | Givaudan Sa | Improvements in or relating to organic compounds |
| CN105658089B (zh) | 2013-10-02 | 2019-07-09 | 奇华顿股份有限公司 | 有机化合物 |
| WO2015050535A1 (en) | 2013-10-02 | 2015-04-09 | Givaudan S.A. | Organic compounds |
| US10834950B2 (en) | 2013-10-02 | 2020-11-17 | Givaudan S.A. | Organic compounds |
| US11122826B2 (en) | 2013-10-02 | 2021-09-21 | Givaudan Sa | Organic compounds |
| WO2015050534A1 (en) | 2013-10-02 | 2015-04-09 | Givaudan S.A. | Organic compounds |
| WO2015048990A1 (en) | 2013-10-02 | 2015-04-09 | Givaudan Sa | Organic compounds having taste-modifying properties |
| WO2015048991A1 (en) | 2013-10-02 | 2015-04-09 | Givaudan Sa | Organic compounds having taste-modifying properties |
| JP7539760B2 (ja) | 2015-07-17 | 2024-08-26 | パシレックス・ファーマシューティカルズ・インコーポレイテッド | Ｎｍｔ２の後成的なサイレンシング |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4778878A (en) * | 1986-08-07 | 1988-10-18 | Washington University | Novel inhibitor peptides I |
| US4778877A (en) * | 1986-08-07 | 1988-10-18 | Washington University | Novel inhibitor peptides II |
-
1990
- 1990-01-25 FR FR9000834A patent/FR2657259A1/fr active Granted
-
1991
- 1991-01-24 PT PT96571A patent/PT96571A/pt not_active Application Discontinuation
- 1991-01-24 JP JP3007188A patent/JPH0717503B2/ja not_active Expired - Lifetime
- 1991-01-24 US US07/645,124 patent/US5164414A/en not_active Expired - Fee Related
- 1991-01-24 IE IE24291A patent/IE65573B1/en not_active IP Right Cessation
- 1991-01-24 CA CA002034861A patent/CA2034861A1/fr not_active Abandoned
- 1991-01-25 ES ES91400163T patent/ES2060310T3/es not_active Expired - Lifetime
- 1991-01-25 AT AT91400163T patent/ATE94387T1/de active
- 1991-01-25 ZA ZA91574A patent/ZA91574B/xx unknown
- 1991-01-25 AU AU69987/91A patent/AU633395B2/en not_active Ceased
- 1991-01-25 OA OA59940A patent/OA09478A/xx unknown
- 1991-01-25 EP EP91400163A patent/EP0443891B1/fr not_active Expired - Lifetime
- 1991-01-25 DE DE91400163T patent/DE69100364T2/de not_active Expired - Fee Related
- 1991-01-25 DK DK91400163.1T patent/DK0443891T3/da active
Non-Patent Citations (2)
| Title |
|---|
| CHEM. PHARM. BULL., vol. 33, no. 1, 1985, pages 282-291; K.-I. NISHIMURA et al.: "Studies on the promoting effects of carboxylic acid derivatives on the rectal absorption of beta-lactam antibiotics in rats" * |
| CHEMICAL ABSTRACTS, vol. 76, no. 20, 15 mai 1972, pages 319-320, abrégé no. 117436g, Columbus, Ohio, US; & JP-A-71 14 357 (AJINOMOTO CO., INC.) 17-04-1971 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5599947A (en) * | 1993-01-14 | 1997-02-04 | G. D. Searle & Co. | Fatty acid analogs and prodrugs |
| US5670650A (en) * | 1993-01-14 | 1997-09-23 | G. D. Searle & Co. | Fatty acid analogs and prodrugs |
| US5672769A (en) * | 1993-01-14 | 1997-09-30 | G. D. Searle & Co. | Fatty acid analogs and prodrugs |
| US5719290A (en) * | 1993-01-14 | 1998-02-17 | G. D. Searle & Co. | Fatty acid analogs and prodrugs |
| US5859052A (en) * | 1993-01-14 | 1999-01-12 | G. D. Searle & Co. | Fatty acid analogs and prodrugs |
| US5929110A (en) * | 1993-01-14 | 1999-07-27 | G. D. Searle & Co. | Fatty acid analogs and prodrugs |
| US5952377A (en) * | 1993-01-14 | 1999-09-14 | G. D. Searle & Co. | Fatty acid analogs and prodrugs |
| US5981580A (en) * | 1993-01-14 | 1999-11-09 | G. D. Searle & Co. | Fatty acid analogs and prodrugs |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE94387T1 (de) | 1993-10-15 |
| DE69100364D1 (de) | 1993-10-21 |
| ES2060310T3 (es) | 1994-11-16 |
| FR2657259B1 (cg-RX-API-DMAC7.html) | 1994-08-19 |
| DE69100364T2 (de) | 1994-04-21 |
| DK0443891T3 (da) | 1993-12-27 |
| JPH04210916A (ja) | 1992-08-03 |
| ZA91574B (en) | 1991-11-27 |
| EP0443891B1 (fr) | 1993-09-15 |
| IE910242A1 (en) | 1991-07-31 |
| EP0443891A1 (fr) | 1991-08-28 |
| AU633395B2 (en) | 1993-01-28 |
| PT96571A (pt) | 1991-10-15 |
| CA2034861A1 (fr) | 1991-07-26 |
| US5164414A (en) | 1992-11-17 |
| JPH0717503B2 (ja) | 1995-03-01 |
| AU6998791A (en) | 1991-08-01 |
| OA09478A (fr) | 1992-11-15 |
| IE65573B1 (en) | 1995-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0443891B1 (fr) | Utilisation de la N-myristoyl-(S)-phénylalanine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation | |
| EP0499521B1 (fr) | Nouveaux inhibiteurs de N-myristoyltransférase, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| Cooper et al. | The enzymatic metabolism of hexobarbital (Evipal) | |
| EP1663219B1 (fr) | Derives d'indole pour le traitement de maladies liees au processus d'epissage | |
| WO2010100133A2 (fr) | Derives indoliques pour le traitement de maladies neurodegeneratives | |
| Vaillant et al. | Effectors of the mammalian plasma membrane NADH-oxidoreductase system. Short-chain ubiquinone analogues as potent stimulators | |
| Murthy et al. | Identification of L-amino acid/L-lysine α-amino oxidase in mouse brain | |
| CA2187200A1 (en) | Nadh oxidase as a target in diagnosis and therapy | |
| Heimark et al. | The preferred solution conformation of warfarin at the active site of cytochrome P-450 based on the CD spectra in octanol/water model system | |
| JPH0283357A (ja) | Ｎ―２，３―ブタジエニルトリー及びテトラアミノアルカン誘導体類 | |
| FR2817749A1 (fr) | Nouvelle utilisation des composes de la classe des chalcones | |
| US5866575A (en) | Method of inhibiting HIV integrase | |
| EP0461237B1 (fr) | Utilisation de derives du 9,10-dihidrophenanthrene pour la preparation d'un medicament anti-tumoral et nouveaux derives | |
| BE1003996A3 (fr) | Peptides sdk, leur procede de preparation ainsi que des compositions therapeutiques en contenant. | |
| EP1954288B1 (fr) | Derives d'amidine et leurs applications a titre de medicament | |
| Srivastava et al. | The effect of propranolol on rat brain catecholamine biosynthesis | |
| EP0203870B1 (fr) | Nouveaux composés de couplage, leur procédé de préparation et leurs applications comme médiateurs dans le développement des effets des interférons | |
| Nestorescu et al. | Ultrastructural localization of pyruvate dehydrogenase in rat heart muscle | |
| EP1993555B1 (fr) | Composition contenant des derives d'amidine ou de carboxamide et des steroides a titre de medicament | |
| JPH07508046A (ja) | オルニチンデカルボキシラーゼを阻害する枝分れアミノオキシアミノアルカン誘導体 | |
| EP0850939B1 (fr) | Dérivés d'ellipticine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| Lazanas | On the Purification and Mechanism of Action of Diamine Oxidases | |
| FR2733235A1 (fr) | Nouveaux dioxazaphosphocanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| Gerulat | The Inhibition of D-amino Acid Oxidase by D-amino Acids and Its Possible Role in the Animal Body |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |